Post-Approval Safety Monitoring Program to Assess the Safety Profile of GARDASIL in China Usual Practice

NCT03659110 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2018-09-27

No results posted yet for this study

Summary

This is a post-Approval Safety Monitoring Program to assess the safety profile of GARDASIL in china usual practice.

Conditions

Interventions

BIOLOGICAL

HPV 4

1000 subjects will be received the HPV 4 vaccine

Sponsors & Collaborators

  • Beijing Chaoyang District Centre for Disease Control and Prevention

    lead OTHER

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2021-07-30
Completion
2021-12-30

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03659110 on ClinicalTrials.gov